Q-omics provides the consensus-scored NKX6-1 profile across patient tissues and cancer cell-line models. NKX6-1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NKX6-1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, NKX6-1 RNA expression shows 10,365 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UVM, HNSC, and ESCA as cancer lineages where NKX6-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NKX6-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NKX6-1 survival associations across molecular data types. NKX6-1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NKX6-1 RNA expression–survival associations across cancer types. High NKX6-1 expression shows unfavorable associations in UVM, KIRC, KIRP and LGG, but favorable associations in SCLC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NKX6-1 RNA expression.
This table summarizes NKX6-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NKX6-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NKX6-1 shows lower tumor expression in THCA and higher tumor expression in HNSC, BRCA, LUSC, KICH and LUAD. The HNSC box plot shows higher NKX6-1 RNA expression in tumor versus normal tissue (log2 FC = +0.781, t-test p < 0.001).
This table shows molecular features associated with NKX6-1 in patient tissues and cancer cell lines. In patient samples, NKX6-1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, NKX6-1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
